Company Performance - Tango Therapeutics reported a quarterly loss of $0.35 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.32, representing an earnings surprise of -9.38% [1] - The company posted revenues of $4.12 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 47.46%, compared to revenues of $5.43 million a year ago [2] - Over the last four quarters, Tango Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - Tango Therapeutics shares have declined approximately 24.6% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for stock performance [4] - The current consensus EPS estimate for the coming quarter is -$0.32 on revenues of $7.24 million, and for the current fiscal year, it is -$1.38 on revenues of $29.51 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Tango Therapeutics belongs, is currently in the top 28% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5] - The Zacks Rank for Tango Therapeutics is currently 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]

Financial Position and Funding - As of December 31, 2024, the company had an accumulated deficit of $501.6 million, primarily due to research and development costs and general administrative expenses [188]. - The company expects to incur significant operating losses for the foreseeable future, with research and development expenses anticipated to increase significantly [188]. - The company completed an $80 million private placement in August 2023 and received $41.7 million in net proceeds from an "at-the-market" stock offering program in January 2024 [194]. - The company will need to raise substantial additional funding to continue operations and advance clinical trial programs [195]. - Future capital requirements may increase significantly due to various factors, including the scope and progress of clinical trials and product development [196]. - The company has not generated any revenue from product sales and will continue to rely on additional financing and collaboration agreements to fund its business objectives [197]. - The company faces challenges in obtaining financing due to disruptions in financial markets and the biopharmaceutical sector [198]. - If the company is unable to obtain funding on acceptable terms, it may have to significantly curtail or discontinue research or development programs [199]. Clinical Development and Trials - The company is actively enrolling patients in two Phase 1/2 clinical trials and expects to begin enrollment in the TNG456 Phase 1/2 clinical trial in the first half of 2025 [194]. - The clinical development process is lengthy and expensive, with uncertain outcomes, and the company may face delays in obtaining regulatory approvals [205]. - Patient enrollment challenges in clinical trials may lead to delays in obtaining necessary regulatory approvals [223]. - The eligibility criteria for clinical trials may limit the pool of available study participants, potentially affecting enrollment rates [224]. - Competition from other companies conducting similar clinical trials may hinder patient enrollment for the company's product candidates [225]. - The company has entered into clinical collaboration agreements with RevMed and Lilly for combination clinical trials, which may impact development timelines [228]. - The complexity of developing combination therapies may lead to increased costs and regulatory challenges [230]. - Clinical trials may face delays due to suspensions or terminations by regulatory authorities, which could impact the approval of product candidates [220]. Regulatory Challenges and Approvals - The company has received FDA clearance for five IND applications but has discontinued development of TNG348 and TNG908 due to safety concerns [202]. - Regulatory agencies may not accept the company's assumptions or analyses, which could adversely affect the likelihood of obtaining regulatory approval [213]. - The company may incur additional costs or experience delays in clinical trials due to various unforeseen events [218]. - The company intends to provide a clinical update on the TNG462 clinical trial and clinical data on the TNG260 clinical trial in 2025 [214]. - The company may seek orphan drug designation for certain product candidates, which could provide financial incentives but does not guarantee market exclusivity [344]. - Breakthrough therapy and fast track designations by the FDA do not guarantee faster development or approval processes for product candidates [348]. - Delays in the regulatory approval process can be costly and negatively impact the timely completion of clinical trials and commercialization efforts [353]. - The company may pursue accelerated approval pathways, but this does not assure a faster regulatory review or increase the likelihood of approval [351]. Intellectual Property Risks - The company faces significant risks related to intellectual property rights, which may not guarantee competitive advantages or commercial success for current or future product candidates [335]. - Significant legal questions exist regarding the patent protection for biopharmaceutical products, with no certainty that patent applications will issue as patents or provide meaningful protection against competitors [301]. - The patent prosecution process is expensive and time-consuming, potentially impacting the ability to file and prosecute necessary patent applications in a timely manner [304]. - The company may face challenges from third parties claiming that its products infringe their patents, which could lead to costly litigation and potential damages [306]. - Market exclusivity for future products will largely depend on patent rights and regulatory protections, with risks of generic competition increasing as exclusivity periods expire [311]. - The company may initiate or become involved in lawsuits to protect its intellectual property rights, which could be expensive and time-consuming [313]. - The company may not be able to obtain adequate patent protection globally, which could impair its ability to prevent competitors from using its technologies [320]. Market and Competitive Landscape - The company faces substantial competition in the biopharmaceutical industry, particularly in the PRMT5 inhibitor space, with competitors like Bristol Myers Squibb, Amgen, and AstraZeneca [253]. - The incidence and prevalence of target patient populations for product candidates have not been precisely established, which could adversely affect revenue and profitability [260]. - The company has never commercialized a product candidate and may face challenges in achieving market acceptance for future products [262]. - Reliance on third parties for clinical trials may lead to delays or inability to obtain regulatory approval if these parties do not meet obligations [265]. Compliance and Regulatory Environment - Compliance with environmental, health, and safety regulations is essential, as violations could lead to fines or penalties that adversely affect business success [371]. - The company's operations may be impacted by potential liabilities associated with the use and disposal of hazardous materials, which could exceed available resources [372]. - Non-compliance with regulatory requirements may lead to penalties, product recalls, or withdrawal from the market [373]. - The company is subject to strict GDPR regulations regarding the processing of personal data, which may increase operational costs and complexity [375]. - Non-compliance with GDPR could result in fines up to €20 million or 4% of total worldwide annual turnover for serious offenses [377]. - Political and trade developments, such as tariffs, could adversely affect the company's financial condition and operations [383].

Clinical Trials and Development - The company is actively enrolling in a Phase 1/2 clinical trial for TNG462, focusing on a 250 mg QD dose expansion cohort with 59 patients across 13 histologies [27] - TNG456 is currently in enrollment for glioblastoma, with a key indication being MTAP-deleted cancers [20] - The company anticipates ongoing enrollment for TNG462 combinations with RAS inhibitors and multiple standard of care regimens throughout the year [29] - The first patient for TNG456 is planned to be dosed in the first half of 2025, targeting glioblastoma patients [11] - TNG456 is set to begin enrollment in a phase 1/2 clinical study in the first half of 2025, focusing on solid tumors with MTAP deletion [67] - TNG462 combination trials enrollment is set to begin in the first half of 2025 [93] - TNG456 Phase 1/2 trial enrollment is also expected to start in the first half of 2025 [93] - TNG260 is currently in a phase 1/2 study with FDA Fast Track designation, targeting STK11 mutations in various cancers [83] - TNG260 clinical data is anticipated to be available in 2025 [88] Efficacy and Safety - TNG462 demonstrates a 43% overall response rate (ORR) in cholangiocarcinoma patients, significantly outperforming competitors like AMG 193 (15% ORR) and BMS-504 (18% ORR) [33] - TNG462 has shown a median progression-free survival (mPFS) of 24 weeks in late-line, difficult-to-treat cancers, indicating durable clinical responses [25] - TNG462 has demonstrated an excellent safety and tolerability profile, with less fatigue and gastrointestinal toxicity compared to competitors [29] - TNG462 demonstrated a median time on treatment of 24 weeks, significantly longer than TNG908's 16 weeks [53] - TNG462 is expected to be more active in MTAP-deleted solid tumors compared to TNG908 and AMG193 [51] - TNG260 has shown complete tumor regression in 5 out of 8 mice in combination with α-PD1, indicating strong potential for immune response [81] - TNG260 is a novel, highly selective CoREST complex inhibitor, currently in Phase 1/2 clinical study evaluating efficacy in combination with pembrolizumab for STK11-mutant cancers [88] Market Potential and Strategic Focus - Approximately 50,000 total treatable MTAP-deleted patients are identified annually in the US, with significant unmet needs in lung and pancreatic cancers [12] - The company plans to initiate first monotherapy registration trials in second-line pancreatic cancer, targeting solid tumors with MTAP deletion [27] - The company plans to initiate registration trials for TNG462 in second-line lung and pancreatic cancer in 2026 [68] - The company is collaborating with Revolution Medicines to evaluate TNG462 in combination with RMC-9805 and RMC-6236 for RAS-mutant cancers [41] - The ongoing dose expansion for TNG260 in STK11-mutant cancers aims to reverse checkpoint inhibitor resistance [88] - STK11 mutations are linked to checkpoint inhibitor resistance in lung cancer patients, highlighting the significance of TNG260 [88] Financial Position - Cash balance stands at $258 million as of December 2024, providing a cash runway into Q3 2026 [93] - The company maintains a strong balance sheet, supporting ongoing clinical trials and future developments [91] - The cash equivalents and marketable securities position the company well for upcoming clinical milestones [93] - The company has multiple projected key milestones, indicating a strong pipeline and strategic focus [91] Comparisons with Competitors - TNG462 has a potency of 4 nM and an MTAP selectivity of 45X, compared to TNG908's 110 nM and 15X [45] - TNG908 showed a 36% overall response rate (ORR) in pancreatic cancer, with 4 out of 11 patients achieving partial responses [48] - TNG456 is predicted to have CNS exposure above the clinical efficacy threshold, targeting MTAP-deleted glioblastoma [60]

Core Insights - Tango Therapeutics has received Orphan Drug Designation for TNG462, aimed at treating pancreatic cancer, which provides marketing exclusivity and incentives upon regulatory approval [6] - The company is focused on advancing its lead PRMT5 program, TNG462, with significant clinical data expected in 2025, particularly for pancreatic and lung cancers [2][5] - TNG456, another PRMT5 inhibitor, has cleared FDA's Investigational New Drug application, with Phase 1/2 trials expected to start in the first half of 2025 [5][7] Pipeline Update - TNG462 is a PRMT5 inhibitor targeting MTAP-deleted cancers, with ongoing Phase 1/2 trials emphasizing pancreatic and lung cancers [3][6] - TNG456 is a next-generation brain-penetrant PRMT5 inhibitor, with preclinical studies indicating improved efficacy for glioblastoma treatment [4][5] - TNG260, a CoREST complex inhibitor, is in a Phase 1/2 trial for lung cancer, with updates expected in 2025 [8][15] Financial Results - As of December 31, 2024, the company reported cash and cash equivalents of $258 million, sufficient to fund operations into the third quarter of 2026 [5][9] - Collaboration revenue for Q4 2024 was $4.1 million, down from $5.4 million in Q4 2023, while total revenue for the year was $42.1 million, compared to $36.5 million in 2023 [10][11] - Research and development expenses increased to $33.9 million for Q4 2024, up from $31.3 million in Q4 2023, reflecting advancements in TNG462 and TNG456 [12] Clinical Collaborations - A clinical collaboration with Eli Lilly has been established to evaluate TNG456 in combination with the CDK4/6 inhibitor Verzenio® for MTAP-deleted solid tumors [5][7] - The FDA granted Fast Track Designation to TNG456 for treating solid tumors with MTAP deletion, facilitating expedited development and review [7] Upcoming Milestones - The company plans to disclose additional clinical data for TNG462 in 2025 and initiate combination studies with other targeted therapies [6][15] - Enrollment for multiple TNG462 combination trials is expected to begin in 2025, alongside the TNG456 Phase 1/2 trial [15]

Core Viewpoint - Tango Therapeutics, Inc. is actively participating in multiple investment bank conferences to showcase its advancements in precision cancer medicines and engage with investors [1]. Group 1: Upcoming Conferences - Tango Therapeutics management will participate in the B Riley Precision Oncology & Radiopharma Conference in New York, NY in late February [1]. - The Leerink Global Healthcare Conference and Barclays 27th Annual Global Healthcare Conference will take place in Miami, FL in March [1]. - The company will be available for 1x1 meetings on Thursday, March 13 [2]. Group 2: Webcast Information - Live webcasts for each event will be available under the "Events & Presentations" tab on the company's website on the day of the event [2]. - A replay of the webcasts will be archived on the company's website for 90 days following the presentations [2]. Group 3: Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision medicine for cancer treatment [4]. - The company utilizes the genetic principle of synthetic lethality to identify and develop therapies targeting critical cancer-related pathways [4].

Core Insights - Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision cancer medicines [1][3] - The company will participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on February 5, 2025 [1] - The event will be accessible via a live webcast and will be archived for 90 days on the company's website [2] Company Overview - Tango Therapeutics is dedicated to discovering novel drug targets and precision medicine for cancer treatment [3] - The company employs the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related targets [3] - More information about the company can be found on their website [3]

Earnings season has begun, and I managed to find a few nuances in Tango Therapeutics (NASDAQ: TNGX ) that motivated me to take a long position via long options on thisHi, I'm Martin, I focus on maintaining a delta neutral portfolio. I want to be long/short at the same time and benefit from market volatility. I specialize in using options through which I enter and exit trades. I look for market opportunities primarily in small companies, and my search takes me into the waters of mid-sized companies as well.A ...

Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.59%. A quarter ago, it was expected that this company would post a loss of $0.34 per share when it actually produced a loss of $0.24, delivering a surprise of 29.41%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights – Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – Next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, TNG456, planned to enter the ...